HER2-positive carcinoma of breast

HER2-positive carcinoma of the breast is a distinct molecular subtype of malignant mammary epithelial neoplasia, representing approximately 15% to 20% of all breast cancer diagnoses Historically associated with high histological grade, accelerated progression, and a greater risk of recurrence and visceral metastases, this subtype is clinically defined by its high susceptibility to targeted anti-HER2 therapeutic agents

HER2-positive carcinoma of the breast is a distinct molecular subtype of malignant mammary epithelial neoplasia, representing approximately 15% to 20% of all breast cancer diagnoses

Pathophysiologically, it is driven by amplification of the *ERBB2* gene or overexpression of the human epidermal growth factor receptor 2 protein, which triggers constitutive receptor tyrosine kinase signaling and uncontrolled cellular proliferation Historically associated with high histological grade, accelerated progression, and a greater risk of recurrence and visceral metastases, this subtype is clinically defined by its high susceptibility to targeted anti-HER2 therapeutic agents

Pathophysiologically, it is driven by amplification of the *ERBB2* gene or overexpression of the human epidermal growth factor receptor 2 protein, which triggers constitutive receptor tyrosine kinase signaling and uncontrolled cellular proliferation

While primarily affecting women, it can also develop in men

Historically associated with high histological grade, accelerated progression, and a greater risk of recurrence and visceral metastases, this subtype is clinically defined by its high susceptibility to targeted anti-HER2 therapeutic agents